Cardiovascular biomarker score and clinical outcomes in patients with atrial fibrillation: a subanalysis of the ENGAGE AF-TIMI 48 randomized clinical trial

CT Ruff, RP Giugliano, E Braunwald… - JAMA …, 2016 - jamanetwork.com
Importance Treatment decisions in atrial fibrillation (AF) are based on clinical assessment of
risk. The CHA 2 DS 2-VASc (cardiac failure or dysfunction, hypertension, age 65-74 [1 point]
or≥ 75 years [2 points], diabetes mellitus, and stroke, transient ischemic attack or
thromboembolism [2 points]–vascular disease, and sex category [female]) risk score is
pragmatic and widely used but has only moderate discrimination. Objective To develop and
test a cardiovascular biomarker score for indication of risk in patients with AF. Design …